An illustration · invented records · this source is real
Prediction of late distant recurrence in patients with oestrogen-receptor-positive breast cancer: a prospective comparison of the breast-cancer index (BCI) assay, 21-gene recurrence score, and IHC4 in the TransATAC study population
Sgroi DC, Sestak I, Cuzick J, Zhang Y, et al. (2013). Lancet Oncology. PubMed 24035531 · DOI 10.1016/S1470-2045(13)70387-5 · PubMed record
What kind of source: Comparison of three tests on archived trial tissue (TransATAC), postmenopausal women. Where it sits in the summary: Not yet known. Back to the summary
What it says, in plain language
In postmenopausal women, the 21-gene score predicted recurrence in the first five years but not later recurrence (years five to ten). Another test did. This marks a limit of what the score can say about the long term.
Source access: this note uses the published abstract, linked above. The full article was not available for this review and is not included in the folder.
The exact words we relied on
“however, only BCI-L was significant for late distant recurrence” — PMID:24035531, Abstract, Findings
How these quotes were checked
Follow the passage links above to the included paper or public source record.
Abstract only. The quotes above come from the paper’s published abstract as held in the PubMed record. They were checked by exact string match against the PubMed record cached on 2026-09-08. This note is limited to the abstract; the full article was not read.
Limits of this source
Archived tissue from one trial; a comparison of prognostic tests, not of treatments. A published correction (PubMed 29611522, Lancet Oncol 2018;19(4):e184, read 2026-09-10) narrows the confidence-interval lines in figure 3 and two appendix graphs, which had been calculated with an incorrect method; the risk curves and the reported findings were not changed. Abstract only.
Review
Reviewed by Sarah Kiselycznyk · September 10, 2026. Review scope and verification method: How we researched this.